Christian Flohr
Immatics Biotechnologies (Germany)(DE)University of Tübingen(DE)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, RNA Interference and Gene Delivery, Hepatitis B Virus Studies, vaccines and immunoinformatics approaches
Most-Cited Works
- → Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival(2012)780 cited
- → HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.(2018)10 cited
- → Abstract 5365: Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide(2012)1 cited
- → Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant) – HEPAVAC(2017)1 cited
- → Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma.(2022)
- → Data from Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma(2023)
- → Abstract A043: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant®): HEPAVAC(2016)
- → Supplementary Data from Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma(2023)
- → Corrigendum to “New vaccination strategies in liver cancer” [Cytokine Growth Factor Rev. 36 (2017) 125–129](2017)